Opinion

Video

Fixed-Duration Options for CLL

Panelists discuss how fixed-duration options like venetoclax plus obinutuzumab show promise in treating chronic lymphocytic leukemia (CLL) by offering defined treatment periods rather than indefinite therapy.

Content above is prompted by the following:

  • A key distinction between preferred upfront therapies for CLL—venetoclax-based regimens and Bruton tyrosine kinase (BTKi)–based regimens—is that venetoclax offers a fixed-duration option, while BTKi therapy is typically continuous. However, studies presented at the 2024 American Society of Hematology annual meeting explored the efficacy and safety of fixed-duration BTKi therapy in the first-line setting. How might adopting fixed-duration BTKi therapy influence treatment choices in the relapsed/refractory CLL setting?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Sundar Jagannath
4 experts in this video
4 experts in this video
Screenshot of a webinar panel discussion with Viet Le, PA-C; Nathan Wong, PhD, MPH; Alison Bailey, MD; and Martha Gulati, MD, MS
World Hepatitis Day graphic | Image Credit: uazzal - stock.adobe.com
2 experts in this video
2 experts in this video
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo